Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Publication rates of heart failure clinical trials still low

05 Jul 2020

A recent study has found that the publication rates of heart failure clinical trial or reporting of results remain “unacceptably low.”

“Under-reporting of clinical trial results inhibits dissemination of knowledge, limits understanding of therapeutic interventions, and may ultimately harm patients,” the investigators said.

A total of 1,429 studies were included, of which 806 (56 percent) were published as manuscripts, 623 were unpublished, and 97 (7 percent) reported results without manuscript publication.

Of these, 1,243 were completed after 2007, when the mean 1-year publication rate for interventional trials rose from 12.7 percent to 19.6 percent (p=0.049), which could have been driven by changes in government regulation. However, no further sustained improvement occurred over time. There was also no multivariable association between later completion dates and reporting or publication of results

Earlier publication was associated with funding from the National Institutes of Health as well as the use of clinical (death, hospitalization, myocardial infarction, changes in functional classification) rather than nonclinical primary endpoints. Notably, whether the results were consistent with the primary hypothesis of the study did not correlate with the likelihood of publication.

“Additional efforts by all stakeholders, including investigators, sponsors, regulators, societies, editors, and journals, are needed to improve data dissemination,” the investigators said.

Cross-sectional analyses of all heart failure clinical trials registered on ClinicalTrials.gov, with at least 2 years of follow-up after trial completion, were evaluated in this study. The investigators chose the content area for the robust clinical trial activity in the field. The primary outcome was manuscript publication with multivariable proportional hazards adjustment to identify associations with publication.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.